Creso Pharma Ltd
ASX:CPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Creso Pharma Ltd
Cash & Cash Equivalents
Creso Pharma Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Creso Pharma Ltd
ASX:CPH
|
Cash & Cash Equivalents
AU$1.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Cash & Cash Equivalents
AU$365.3k
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Cash & Cash Equivalents
AU$59.8m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Cash & Cash Equivalents
AU$4.2m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-13%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Cash & Cash Equivalents
AU$47.7m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Cash & Cash Equivalents
AU$35.6m
|
CAGR 3-Years
31%
|
CAGR 5-Years
20%
|
CAGR 10-Years
14%
|
|
Creso Pharma Ltd
Glance View
Creso Pharma Ltd. develops, registers and commercializes pharmaceutical-grade cannabis and hemp-hemp-derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health. The firm is engaged in developing cannabis and hemp-derived therapeutic-grade nutraceuticals and medical cannabis products with a range of applications in both human and animal health. The Company, through its subsidiary is also engaged in cultivates and harvests cannabis plants and supplies dried cannabis plant retail products. The firm is operating medical facility in Windsor, Nova Scotia with 6 treatment rooms and a laboratory dedicated to performing psychedelic-assisted psychotherapy and clinical research.
See Also
What is Creso Pharma Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
1.4m
AUD
Based on the financial report for Dec 31, 2022, Creso Pharma Ltd's Cash & Cash Equivalents amounts to 1.4m AUD.
What is Creso Pharma Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 1Y
-81%
Over the last year, the Cash & Cash Equivalents growth was -81%.
